

ILE INTRAVENOUS LIPID EMULSION THERAPY FOR TOXICITIES

Brian C. Young, VMD, DACVIM (Internal Medicine), DACVECC



Animal Specialty Group

Specialized Treatment + **Compassionate** Care

Welcome Dr. Nicole DeNezzo!



Objectives


- Introduce a novel treatment modality for life-threatening toxicoses
- Provide background
- Review human and veterinary literature
- Discuss infusion protocol and adverse effects



Background

- ILE used in human medicine for the past decade to treat local anesthetic overdose
- ILE useful to rescue patients poisoned with lipophilic substances failing traditional therapy






ILE is **treatment of choice** for local anesthetic systemic toxicosis in humans

- Association of Anesthesiologists of Great Britain and Ireland
- American Society of Critical Care Anesthesiologists
- American Society of Anesthesiologists Committee on Critical Care Medicine
- Resuscitation Council of the UK
- American Society of Regional Anesthesia


Lipid emulsions

- Intralipid 20% solution (10-30%), 500 and 1000 ml bags
- Neutral, medium to long-chain triglycerides derived from plant oils (soybean), egg phosphatides, and glycerin
- Fat droplets similar to endogenous chylomicrons





20% Intralipid

- Component of TPN (mixed with amino acids, dextrose, vitamins and minerals)
 - Highly susceptible to bacterial contamination
 - Shelf life of two years
- 

Mechanism of action?

1. Sequestration="lipid sink";
lipid forms new compartment
 - Supported by visible sequestration of lipophilic dye in a dose-dependent manner
 - Dye had same lipid solubility as bupivacaine/lidocaine
 - May not explain rapidity of hemodynamic stabilization




What happens to toxins?

- Peak plasma levels of drug may be observed after ILE (bupropion, ivermectin), supporting lipid sink theory
- Circulating lipoprotein lipase hydrolyzes triglycerides, releasing FFA
- FFA taken up & cleared by skeletal muscle, splanchnic viscera, myocardial, and subcutaneous tissue
- In cells FFA transported to mitochondria via carnitine translocase to undergo beta oxidation, producing ATP
- Toxins are likely degraded in lysosomes

MOA: improved myocardial function


2. Metabolic theory:
FFA improve myocardial ATP production and function
 - 80-90% myocardial energy from FFA
 - Local anesthetics inhibit FFA from entering mitochondria (carnitine translocase)



Jennifer Korsen, artist

Third mechanism

3. LCFA activate voltage-dependent Ca channels, increase intracellular Ca & inotropy
 - This may be detrimental in ischemic tissue



Lipid-soluble toxins

- **Local anesthetics** (lidocaine, bupivacaine)
- **Avermectin parasiticides** (ivermectin, moxidectin)
- **Beta-blockers**
- **Ca channel-blockers** (diltiazem, amlodipine)
- Digoxin
- Amiodarone
- Baclofen
- **Anti-depressants** (fluoxetine, sertraline, paroxetine, imipramine, clomipramine, amitriptyline, doxepin, bupropion, trazadone)
- **Antihistamines** (chlorpheniramine, promethazine, doxepin)
- Chlorpromazine
- Itraconazole
- Loratadine
- Nicotine
- **Insecticides** (permethrin/pyrethrin, organophosphates, carbamates)
- Illicit drugs (marijuana, methamphetamine, cocaine)
- **Anti-epileptic drugs** (phenobarbital, lamotrigine, carbamazepine)
- Loperamide
- Bromethalin
- CCNU, vinblastine
- Minoxidil
- Hydrochloroquine
- **NSAIDS** (carprofen, indomethacin, ketoprofen, naproxen)
- Cyclosporin
- Dexamethasone
- Diazepam
- Haloperidol

Literature review

- Limitations of case reports:
 - correlation does not equal causation
- Randomized, controlled trials needed to evaluate efficacy



Lipid Emulsion Infusion Rescues Dogs From Bupivacaine-Induced Cardiac Toxicity

Guy Weinberg, M.D., Richard Ripper, B.A., Douglas L. Feinstein, Ph.D., and William Hoffman, Ph.D.

- 10 mg/kg bupivacaine IV
- Causes impaired fatty acid oxidation by inhibiting carnitine translocase, blocking ATP production → negative inotropy/chronotropy
- Cardiopulmonary arrest and CPR x 10 minutes
 - lipid rescue 100% survival (4 ml/kg over 2 minutes followed by 0.5 ml/kg/min x 10 minutes)
 - saline placebo 0% survival
- ILE direct inotropic effects most likely

Moxidectin toxicosis in a puppy successfully treated with intravenous lipids

Dawn E. Crandell, DVM, DVSc, DACVECC and Guy L. Weinberg, MD

- First clinical veterinary case report
- Moxidectin terminal elimination half life in dog 25.9 days
- 16 week-old FI Jack Russell Terrier
- Contact with horses treated with dewormer
- Vomiting, ataxia, seizuring; progressed to coma, bradycardia (HR 60) & hypoventilation (SpO₂ 88% pvCO₂ 72.3)
- Mechanical ventilation, fluids, diazepam, & activated charcoal given




Clinical course

- 5.5 hours post admission: 2 ml/kg ILE, then 4 ml/kg/hr x 4 hours
- Within 2 hours of ILE, RE improved and PPV discontinued, but could not be extubated
- 11 hours after lipids: swallowing & extubated
- 24 hours after toxin exposure: 2nd lipid bolus (15 ml/kg given over 30 minutes)
- 30 minutes later: ambulatory. Behavior improved over next few hours. 6 hours later: ate well, off diazepam CRI with no more seizures

Use of intravenous lipid emulsion to treat ivermectin toxicosis in a Border Collie

Dana L. Clarke, VMD, DACVECC; Justine A. Lee, DVM, DACVECC; Lisa A. Murphy, VMD; Erica L. Reineke, VMD, DACVECC

- 2 year-old FS Border Collie
- Ingested equine dewormer and developed lethargy, ataxia, tremors, blindness
- ABCB₁-1Δ polymorphism suspected
- Canine ivermectin toxicities have required long term mechanical ventilation
- 80 hour half life



Clinical course

- 20% Intralipid 1.5 ml/kg bolus over 10 minutes, CRI 0.25 ml/kg/min for 60 minutes
- 6 hours later: more responsive & ambulatory, remained ataxic
- 12 hours: ILE repeated, after which dog much better, tremors minimal, improved mydriasis
- Discharged & made a full recovery with return of vision

Additional testing

- No ABCB₁-1Δ mutation
- Ivermectin blood levels increased immediately after ILE doses, suggesting a lipid sink mechanism
- Ivermectin blood levels decreased over time

Lipid infusion in the management of poisoning: a report of 6 canine cases

N. Bates, J. Chatterton, C. Robbins, K. Wells, J. Hughes, M. Stone, A. Campbell

- 3 ivermectin
- 2 moxidectin
- 1 baclofen
- All dogs improved by 4.5 hours after ILE
- Only adverse effect was swelling and pain due to extravasation of lipids
- All discharged by 52 hours after exposure and made full recoveries

Treatment of Ibuprofen Toxicosis in a Dog with IV Lipid Emulsion

Luiz Bolfer, DVM, Maureen McMichael, DVM, DACVECC, Thandeka R. Ngwenyama, DVM, Mauria A. O'Brien, DVM, DACVECC

- 3 year-old FS mixed breed dog
- 1856 mg/kg ibuprofen (180 tablets)
- Became obtunded and then comatose, tachycardic, and hypotensive within 30 minutes
- Treatment with prostaglandin analogs, naloxone, and antiemetics
- Clinical signs improved 3 hours after ILE and patient discharged 3 days later

Use of IV Lipid Emulsion for Treatment of Ivermectin Toxicosis in a Cat

James H. Kidwell, BS*, Gareth J. Buckley, MA, VetMB, DACVECC, Ashley E. Allen, DVM, Carsten Bandt, DVM, DACVECC

- 1 y MC DSH ingested equine ivermectin paste
- Laterally recumbent, lethargic, tachycardic, hyperesthetic
- Treated with IV fluids
- 24h later: obtunded, hypothermic, hypoxemic



Clinical course

- 4 ml/kg 20% Intralipid; 3 ml/kg/h x 4 hours; became lipemic
- 5 hours later: responsive, but remained non-ambulatory
- Next day: 2nd lipid infusion 3 ml/kg/hr x 2 h (lipemia had resolved); began swallowing
- 4 days after ingestion: discharged, mild ataxia resolved at home

Infusion of a lipid emulsion to treat lidocaine intoxication in a cat

Taylor Q. O'Brien, DVM; Stuart C. Clark-Price, DVM, MS, DACVIM, DACVA;
Erika E. Evans, DVM; Renata Di Fazio, DVM; Maureen A. McMichael, DVM, DACVECC

- 5 y MC DSH presented after 20.5 mg/kg SQ lidocaine for wound debridement
- Lethargic, dyspneic, non-responsive, poor perfusion
- 20% Intralipid 3 ml/kg over 60 minutes
- Patient became more responsive within 15 minutes
- Made a full recovery



Intravenous lipid emulsion for treating permethrin toxicosis in a cat


- 2 year-old cat
- Seizures, tremors, hypersalivation after permethrin toxicity
- Treated with bathing, methocarbamol, and ILE
- Recovered and discharged in 42 hours

Animal studies

- Yoav 2002: significantly lower mortality in rats poisoned with **clomipramine** receiving ILE vs saline
- Harvey 2007: faster recovery of BP in **clomipramine** rabbit toxicity
- Bania 2007: showed improved survival with ILE vs saline (7/7 vs 1/7) in dogs poisoned with **verapamil**

Human case reports

- Cardiopulmonary arrest (4-20 minutes) in three patients with **local anesthetic overdose**.
 - Successfully rescued with ILE¹⁻³
 - All survived and fully recovered



1. Rosenblatt *Anesthesiology* 2006 2. Litz *Anaesthesia* 2006 3. Foxall *Anaesthesia* 2007

Human literature

- Person overdosed on **bupropion**, comatose, suffered cardiopulmonary arrest x50 minutes and was successfully resuscitated with ILE
 - Serial blood levels of bupropion consistent with lipid sink (higher after infusion)

Evidence-based?

- Lack of prospective, randomized trials
- Outcome difficult to attribute to ILE vs other treatment measures
- Considered “experimental” at this time and should be **reserved for severe intoxications**
- Used *in addition to* **not** instead of traditional therapies




Infusion protocol

*as recommended by ASPCA Animal Poison Control

- Requires a dedicated IV catheter (do not mix with fluids)
- Aseptic technique (gloves to prepare infusion)
- *Only 20% solution*, through a 1.2 micron **TPN filter**
- 1.5 ml/kg over 5 minutes
- 0.25 ml/kg/min for 30-60 minutes
- Repeat in four hours if no **lipemia** (spin down hematocrit tubes); do not repeat if serum orange or yellow
- Limit of 8 ml/kg/d
- Refrigerate between uses
- Discard bag 24 hours after opening

Filter?

- Filter out small particles that may lead to fat emboli
- Trap any air bubbles present



Recurrent toxicity

- Cardiotoxicity may recur after ILE infusion
 - Toxin may come out of lipid solution or may not be fully taken up
 - Toxin may be released as lipid is metabolized
- Monitor patients and consider repeating ILE if clinical signs recur

Adverse effects

- Major adverse effects are **RARE**
- Lipemia
- Possible pancreatitis secondary to lipemia
- Interference with therapeutic drugs: anti-convulsants, insulin
- Immune cell dysfunction secondary to lipids
- May worsen oxygenation in ARDS patients



Adverse effects

- Hypersensitivity reactions to soybean or egg protein:
 - fever, nausea, vomiting within 20 minutes
- Lipid emboli, thrombosis, thrombocytopenia
- Laboratory errors:
 - false elevation of glucose, methemoglobin
 - affects AST, amylase, phosphorus, creatinine
- Fat overload syndrome--hyperlipidemia with:
 - hemolysis, jaundice, seizures, prolonged clotting time, thrombocytopenia, fat embolism
- Lipids promote bacterial growth
- Phlebitis
- Safety studies LD₅₀ in rats 68 ml/kg!

References

- Bania T et al. Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline. *Acad Emerg Med* 2007;14:105-111.
- Bates N et al. Lipid infusion in the management of poisoning: a report of 6 canine cases. *Vet Rec* 2013;172:339-342.
- Bolfer L et al. Treatment of ibuprofen toxicosis in a dog with IV lipid emulsion. *JAAHA* 2014;50:136-140.
- Cave G and M Harvey. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systemic review. *Ann Emerg Med* 2009;16:815-824.
- Cave G et al. Review article: intravenous lipid emulsion as antidote: a summary of published human experience. *Emerg Med Aust* 2011;23:123-141.
- Clarke DL et al. Use of intravenous lipid emulsion to treat ivermectin toxicosis in a Border Collie. *JAVMA* 2011;239:1328-1333.
- Crandell DE and GL Weinberg. Moxidectin toxicosis in a puppy successfully treated with intravenous lipids. *JVECC* 2009;19(2):181-186.
- DeGroot WD. Intravenous lipid emulsion for treating permethrin toxicosis in a cat. *Can Vet J* 2014;55(1):1253-1254.
- Fernandez AL et al. The use of intravenous lipid emulsion as an antidote in veterinary toxicology. *JVECC* 2011;21(4):309-320.
- Foxall G et al. Levovupivacaine-induced seizures and cardiovascular collapse treated with Intralipid. *Anaesthesia* 2007;62:516-518.
- Gwaltney-Brant S and I Meadows. Use of intravenous lipid emulsions for treating certain poisoning cases in small animals. *Vet Clin Small Anim* 2012;42:251-262.
- Harvey M and G Cave. Intralipid outperforms sodium bicarbonate in a rabbit model of clomipramine toxicity. *Ann Emerg Med* 2009;16:151-156.

References continued

- Kaplan A and M Whelan. The use of lipid emulsion for lipophilic drug toxicities. *JAAHA* 2012;48:221-227.
- Kidwell JH et al. Use of IV lipid emulsion for treatment of ivermectin toxicosis in a cat. *JAAHA* 2014;50:59-61.
- Litz RJ et al. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. *Anaesthesia* 2006;61:800-807.
- O'Brien TO et al. Infusions of a lipid emulsion to treat lidocaine intoxication in a cat. *JAVMA* 2010;237:1455-1458.
- Papadopoulou A. The use of dye surrogates to illustrate local anesthetic drug sequestration by lipid emulsion. *Regional Anes & Pain Med* 2012;37(2):183-187.
- Rosenblatt MA et al. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. *Anesthesiology* 2006;105:217-218.
- Sirlanni AJ et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. *Ann Emerg Med* 2008;51(4):412-5.
- Turner-Lawrence DE and W Kerns. Intravenous fat emulsion: a potential novel antidote. *J Med Tox* 2008;4(2):109-114.
- Waring WS. Intravenous lipid administration for drug-induced toxicity: a critical review of the existing data. *Expert Rev Pharm* 2012;5(4):437-444.
- Weinberg G, et al. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. *Reg Anes Pain Med* 2003;28(3):198-202.
- Yaov G et al. A lipid emulsion reduces mortality from clomipramine overdose in rates. *Vet Hum Toxicol* 2002;44:30.

Thank you! Questions?

